In this episode we discuss John Ioannidis' article on the uselessness of medical conferences, published in JAMA: "Are Medical Conferences Useful? And for Whom?", followed by an interview with return-guest Dr. Adam Obley on a few recent clinical trials: Vascepa, fish oil, vitamin D, and methotrexate.

In this episode, we tackle the recent papers in the New England Journal of Medicine on "Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma" and "Immunotherapy Combinations in Multiple Myeloma", as well as a comment in The Lancet Oncology's editorial "9 Weeks That Matter for Patients With Gastric Cancer". We conclude with an interview with Dr. Erick Turner of OHSU on the FDA, regulatory capture, selective reporting, and transparency.

In this episode we question the conclusions of the phase II trial "Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma", review the long-term overall survival results from PALOMA-3, discuss Dr. Gyawali et al.'s paper on the need for transparency in reporting harms from cancer drugs, and interview Dr. Talal Hilal from the Scottsdale Mayo Clinic on his advice for trainees.

We begin this episode analyzing the unrepentant hype of precision oncology in a monologue that was originally one half of a debate titled: "Is Precision Oncology Generating Patient Benefit or Just Hype?" We conclude with an interview with Dr. Andrae Vandross on the mentor/mentee relationship.

In this episode we evaluate the IMpassion130 trial on the use of atezolizumab in triple-negative breast cancer. We also interview Dr. Brian Chan of OHSU on a randomized controlled trial he's running that tests whether Dr. Gawande's idea of "hot-spotting" -- tailoring interventions to medically complex patients -- does decrease hospitalizations. IMpassion130: doi.org/10.1056/NEJMoa1809615 Hot-spotting: https://www.newyorker.com/magazine/2011/01/24/the-hot-spotters

This BONUS episode is the recording of the Hospitalist Grand Rounds given at Oregon Health & Science University on October 11, 2018. The talk is on medical reversal. Before the talk we discuss the paper "Many Analysts, One Data Set: Making Transparent How Variations in Analytic Choices Affect Results" by Silberzahn et al., published in Advances in Methods and Practices in Psychological Science. Paper: doi.org/10.1177/2515245917747646

In this episode we review the recent paper in Nature Reviews Clinical Oncology by Booth, C.M. and Detsky, A.S. titled "Why patients receive treatments that are minimally effective?". We discuss the failure of CheckMate 331 to meet its primary endpoint despite having received accelerated FDA approval. Finally, we bring back Dr. Adam Obley (from episode 1.01) to talk about low-value healthcare, medical education, social media, and more!

Listen in for a breakdown of the good and the bad of KEYNOTE-189 (trial published in NEJM), a discussion with Dr. Talal Hilal of the Mayo Clinic on the rise of minimal residual disease as a clinical endpoint, and an interview with Dr. Adam Cifu of the University of Chicago Pritzker School of Medicine on medical education, sham trials, and more.

This BONUS episode is the recording of a Grand Rounds talk given at Oregon Health & Science University on September 19, 2018. The talk was inspired by the article by JPA Ioannidis titled "Evidence-based medicine has been hijacked: a report to David Sackett", published May 2016 in the Journal of Clinical Epidemiology.

We discuss Dr. Califf's comment on the "social media peanut gallery of experts", Dr. Drazen's comment on "research parasites" and his retirement from NEJM, the recent paper in JAMA on long-term follow up for antibiotics as compared to appendectomies, and the paper in JAMA Internal Medicine on the relationship between health-related quality of life and progression-free survival. Finally, we interview Dr. Bishal Gyawali on a variety of topics, including cancer groundshot.

Today we tackle some cardiologists' opposition to criticizing clinical trials on Twitter, the PACIFIC trial on durvalumab in stage III non–small-cell lung cancer, and the recent paper in Heart: "Percutaneous Coronary Intervention for Stable Coronary Artery Disease" by R.K. Al-Lamee, A.N. Nowbar, and D.P. Francis. We end with an interview on academic medical publishing with Dr. Rebecca Cooney, North American Executive Editor of The Lancet.

Special episode! We discuss the recent correspondence in NEJM on response rate in phase I clinical trials, the JACOB trial published in The Lancet Oncology on pertuzumab for HER2-positive gastric cancer, and we give an evaluation of MI, stroke, and metastasis as hard endpoints.

In this episode we discuss hyperprolific authors and the recent comment in Nature by JPA Ioannidis, R Klavans, & KW Boyack; NCCN guidelines with fourth-year medical student Jeffrey Wagner; and point-of-care ultrasounds with Dr. Renee Dversdal of OHSU.

In this episode we discuss the USA FDA's recent approval of sunitinib as the adjuvant treatment for patients with resected renal cell carcinoma who are at high risk of relapse. We also interview cardiologist Dr. John Mandrola on new directions forward for evidence-based medicine.

In this episode we break down the RELEVANCE trial published in the New England Journal of Medicine; discuss big data in observational studies with Jenny Gill, MS; and interview Dr. Catherine Livingston of OHSU, an expert in healthcare policy, on her work with the Oregon Health Authority and state Medicaid.

In this episode we cover the cost and efficacy of cancer drugs; review ECHELON-1; interview Dr. Derrick Tao of OHSU about his recent Lancet Oncology paper on poor control arms; and discuss evidence-based medicine with EBM expert and internist at OHSU, Dr. Martha Gerrity.